BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 29774626)

  • 1. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings.
    Carrió M; Gel B; Terribas E; Zucchiatti AC; Moliné T; Rosas I; Teulé Á; Ramón Y Cajal S; López-Gutiérrez JC; Blanco I; Castellanos E; Lázaro C; Stemmer-Rachamimov A; Romagosa C; Serra E
    Hum Mutat; 2018 Aug; 39(8):1112-1125. PubMed ID: 29774626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
    Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
    Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
    Beert E; Brems H; Daniëls B; De Wever I; Van Calenbergh F; Schoenaers J; Debiec-Rychter M; Gevaert O; De Raedt T; Van Den Bruel A; de Ravel T; Cichowski K; Kluwe L; Mautner V; Sciot R; Legius E
    Genes Chromosomes Cancer; 2011 Dec; 50(12):1021-32. PubMed ID: 21987445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1.
    Pasmant E; Sabbagh A; Masliah-Planchon J; Ortonne N; Laurendeau I; Melin L; Ferkal S; Hernandez L; Leroy K; Valeyrie-Allanore L; Parfait B; Vidaud D; Bièche I; Lantieri L; Wolkenstein P; Vidaud M;
    J Natl Cancer Inst; 2011 Nov; 103(22):1713-22. PubMed ID: 22034633
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Chaney KE; Perrino MR; Kershner LJ; Patel AV; Wu J; Choi K; Rizvi TA; Dombi E; Szabo S; Largaespada DA; Ratner N
    Cancer Res; 2020 Nov; 80(21):4720-4730. PubMed ID: 32816910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation.
    Rhodes SD; He Y; Smith A; Jiang L; Lu Q; Mund J; Li X; Bessler W; Qian S; Dyer W; Sandusky GE; Horvai AE; Armstrong AE; Clapp DW
    Hum Mol Genet; 2019 Aug; 28(16):2752-2762. PubMed ID: 31091306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.
    Mußotter T; Kluwe L; Högel J; Nguyen R; Cooper DN; Mautner VF; Kehrer-Sawatzki H
    BMC Med Genet; 2012 Oct; 13():98. PubMed ID: 23101500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
    Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
    Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.
    Nielsen GP; Stemmer-Rachamimov AO; Ino Y; Moller MB; Rosenberg AE; Louis DN
    Am J Pathol; 1999 Dec; 155(6):1879-84. PubMed ID: 10595918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.
    Miettinen MM; Antonescu CR; Fletcher CDM; Kim A; Lazar AJ; Quezado MM; Reilly KM; Stemmer-Rachamimov A; Stewart DR; Viskochil D; Widemann B; Perry A
    Hum Pathol; 2017 Sep; 67():1-10. PubMed ID: 28551330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors.
    Perry A; Roth KA; Banerjee R; Fuller CE; Gutmann DH
    Am J Pathol; 2001 Jul; 159(1):57-61. PubMed ID: 11438454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical neurofibromas reveal distinct epigenetic features with proximity to benign peripheral nerve sheath tumor entities.
    Kresbach C; Dottermusch M; Eckhardt A; Ristow I; Paplomatas P; Altendorf L; Wefers AK; Bockmayr M; Belakhoua S; Tran I; Pohl L; Neyazi S; Bode H; Farschtschi S; Well L; Friedrich RE; Reuss D; Snuderl M; Hagel C; Mautner VF; Schüller U
    Neuro Oncol; 2023 Sep; 25(9):1644-1655. PubMed ID: 36866403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal origin of tumor cells in a plexiform neurofibroma with LOH in NF1 intron 38 and in dermal neurofibromas without LOH of the NF1 gene.
    Däschner K; Assum G; Eisenbarth I; Krone W; Hoffmeyer S; Wortmann S; Heymer B; Kehrer-Sawatzki H
    Biochem Biophys Res Commun; 1997 May; 234(2):346-50. PubMed ID: 9177273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas.
    Kluwe L; Friedrich RE; Korf B; Fahsold R; Mautner VF
    Hum Mutat; 2002 Mar; 19(3):309. PubMed ID: 11857752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis.
    Lévy P; Bièche I; Leroy K; Parfait B; Wechsler J; Laurendeau I; Wolkenstein P; Vidaud M; Vidaud D
    Clin Cancer Res; 2004 Jun; 10(11):3763-71. PubMed ID: 15173083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.
    Carrió M; Mazuelas H; Richaud-Patin Y; Gel B; Terribas E; Rosas I; Jimenez-Delgado S; Biayna J; Vendredy L; Blanco I; Castellanos E; Lázaro C; Raya Á; Serra E
    Stem Cell Reports; 2019 Feb; 12(2):411-426. PubMed ID: 30713041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.
    Steinmann K; Kluwe L; Friedrich RE; Mautner VF; Cooper DN; Kehrer-Sawatzki H
    J Invest Dermatol; 2009 Mar; 129(3):615-21. PubMed ID: 18800150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
    Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
    Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclassification of nerve sheath tumors by gene expression profiling.
    Holtkamp N; Reuss DE; Atallah I; Kuban RJ; Hartmann C; Mautner VF; Frahm S; Friedrich RE; Algermissen B; Pham VA; Prietz S; Rosenbaum T; Estevez-Schwarz L; von Deimling A
    Brain Pathol; 2004 Jul; 14(3):258-64. PubMed ID: 15446580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.
    Mitchell DK; Burgess B; White EE; Smith AE; Sierra Potchanant EA; Mang H; Hickey BE; Lu Q; Qian S; Bessler W; Li X; Jiang L; Brewster K; Temm C; Horvai A; Albright EA; Fishel ML; Pratilas CA; Angus SP; Clapp DW; Rhodes SD
    Clin Cancer Res; 2024 Mar; 30(5):1038-1053. PubMed ID: 38127282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.